## Correct Answer Analysis **Key Point:** Loop diuretics are NOT first-line antihypertensives in CKD. They are reserved for volume overload (edema, pulmonary congestion) or advanced CKD (eGFR <30). ACE-I/ARB are first-line for CKD with albuminuria; thiazide-type diuretics are preferred for volume-replete, non-albuminuric CKD. ## Why Each Option Is Correct (Except the Answer) ### Option 0: ACE Inhibitors in Non-Diabetic CKD - **High-Yield:** ACE-I/ARB reduce intraglomerular pressure, decrease proteinuria, and slow GFR decline in CKD with albuminuria (both diabetic and non-diabetic). - **Clinical Pearl:** This is a cornerstone of renal protection and is guideline-endorsed (KDIGO 2021). ### Option 1: SGLT2 Inhibitors - **High-Yield:** SGLT2i (empagliflozin, dapagliflozin) reduce CKD progression and cardiovascular death independent of glucose lowering or baseline diabetes status. - **Clinical Pearl:** The DAPA-CKD and EMPA-KIDNEY trials demonstrated ~25–30% reduction in CKD progression or renal death. - This is now standard of care in CKD stage 3–4. ### Option 2: Finerenone - **High-Yield:** Finerenone is a non-steroidal MRA that reduces CKD progression, albuminuria, and cardiovascular events in both diabetic and non-diabetic CKD. - The FIDELITY analysis and FIDELIO-DKD trial established its role as an adjunctive agent to ACE-I/ARB and SGLT2i. ### Option 3: Loop Diuretics (THE WRONG STATEMENT) - Loop diuretics are NOT first-line antihypertensives in CKD. - **Warning:** Using loop diuretics as monotherapy for BP control in non-volume-overloaded CKD patients can worsen renal function and electrolyte abnormalities. - Appropriate use: volume overload, advanced CKD (eGFR <30), or acute decompensation. - First-line agents: ACE-I/ARB (albuminuria), thiazide-type diuretics (non-albuminuric), or calcium channel blockers. ## Treatment Algorithm for CKD Hypertension ```mermaid flowchart TD A[CKD with Hypertension]:::outcome --> B{Albuminuria present?}:::decision B -->|Yes| C[ACE-I or ARB first-line]:::action B -->|No| D{Volume overloaded?}:::decision D -->|Yes| E[Thiazide-type diuretic or loop diuretic]:::action D -->|No| F[Thiazide-type diuretic or CCB]:::action C --> G[Add SGLT2i if eGFR 20-90]:::action G --> H[Consider finerenone if albuminuria persists]:::action E --> I[Avoid loop diuretics if volume-replete]:::urgent ``` ## Key Guideline Points (KDIGO 2021) | Agent | Indication | Mechanism | Evidence Level | |-------|-----------|-----------|----------------| | ACE-I/ARB | Albuminuria + CKD | ↓ GFR decline, ↓ proteinuria | Strong | | SGLT2i | CKD stage 3–4, any albuminuria | ↓ Progression, CV benefit | Strong | | Finerenone | Albuminuria + CKD (add-on) | Non-steroidal MRA | Moderate | | Loop diuretics | Volume overload only | Natriuresis | Conditional | | Thiazide-type | Non-albuminuric CKD | BP control | Moderate | **Clinical Pearl:** The combination of ACE-I/ARB + SGLT2i + finerenone represents modern triple therapy for CKD with albuminuria and is increasingly used in stage 3–4 CKD.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.